Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer

Table 4

Prognostic factors for disease specific survival after primary debulking surgery (a) and after interval debulking surgery (b).

(a)

	Univariable analysis			Multivariable analysis
	HR	95% CI	value	HR	95% CI	value
Age (years)	1.00	0.99–1.02	0.55	1.01	0.99–1.03	0.47
FIGO stage IV	1.46	0.82–2.58	0.20	1.06	0.45–2.47	0.90
WHO performance ≥ 1	2.02	1.44–2.85	<0.001	2.01	1.32–3.07	<0.001
ASA ≥ 2	1.10	0.78–1.56	0.59	0.80	0.38–0.80	0.38
Histology
HGS and undifferentiated	1			1
Low grade serous	0.39	0.10–1.58	0.19	0.19	0.03–1.45	0.11
Mucinous	1.93	1.04–3.60	0.04	2.93	1.38–6.20	0.01
Endometrioid	0.83	0.50–1.36	0.46	0.81	0.41–1.62	0.56
Clear cell	1.81	0.95–3.48	0.07	2.69	1.29–5.62	0.01
CA 125 before treatment	1.07	0.98–1.18	0.15	0.97	0.84–1.11	0.63
Intraoperative ascites > 500 ml	1.35	0.97–1.06	0.08	0.89	0.56–1.41	0.61
Extensive surgery	0.85	0.61–1.18	0.34	0.84	0.55–1.27	0.41
Residual disease
NRD	1			1
MRD	1.48	0.99–2.21	0.05	2.04	1.11–3.76	0.02
GRD	1.64	1.13–2.39	0.01	1.84	1.05–3.21	0.03

(b)

	Univariable analysis			Multivariable analysis
	HR	95% CI	value	HR	95% CI	value
Age (years)	1.01	1.00–1.02	0.03	1.02	0.99–1.03	0.06
FIGO stage IV	1.09	0.85–1.38	0.51	1.17	0.80–1.71	0.41
WHO performance ≥ 1	1.32	1.03–1.68	0.03	0.96	0.70–1.32	0.80
ASA ≥ 2	1.19	0.93–1.53	0.16	1.06	0.75–1.49	0.75
Histology
HGS and undifferentiated	1			1
Low grade serous	0.66	0.29–1.49	0.32	0.34	0.11–1.08	0.08
Mucinous	1.49	0.74–3.03	0.27	2.05	0.74–5.73	0.17
Endometrioid	0.77	0.41–1.46	0.43	1.24	0.64–2.40	0.53
Clear cell	1.08	0.51–2.31	0.83	1.48	0.60–3.71	0.40
CA 125 before treatment				0.94	0.84–1.05	0.25
Intraoperative ascites > 500 ml	1.68	1.26–2.24	<0.001	1.41	0.93–2.15	0.10
Extensive surgery	0.92	0.73–1.16	0.49	1.09	0.86–1.37	0.08
Residual disease						<0.001
NRD	1			1
MRD	1.87	1.47–2.39	<0.001	1.79	1.26–2.53	<0.001
GRD	3.42	2.48–4.72	<0.001	3.11	2.01–4.81	<0.001

HR: hazard ratio, CI: confidence interval, HGS: high grade serous, NRD: no residual disease, MRD: minimal residual disease (deposits of residual tumour <1 cm), and GRD: gross residual disease (deposits of residual tumour >1 cm).